JPH09502978A - 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法 - Google Patents
免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法Info
- Publication number
- JPH09502978A JPH09502978A JP7509897A JP50989795A JPH09502978A JP H09502978 A JPH09502978 A JP H09502978A JP 7509897 A JP7509897 A JP 7509897A JP 50989795 A JP50989795 A JP 50989795A JP H09502978 A JPH09502978 A JP H09502978A
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- carbohydrate
- component
- cdap
- immunogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.免疫原性構成物の製造方法であって、 a) シアン化試薬を使って少なくとも1つの第一の炭水化物含有成分を活性化 し;そして b) 前記活性化された炭水化物を第二成分に共有結合により結合させる ことを含んで成る方法。 2.免疫原性構成物の製造方法であって、 a) シアン化試薬を使って少なくとも1つの第一の炭水化物含有成分を活性化 し; b) 前記第一成分を二価性スペーサー試薬に共有結合により結合させ;そして c) 第二成分を段階b)の二価性スペーサー試薬に共有結合により結合させる ことを含んで成る方法。 3.前記シアン化試薬がCDAP、CTEAおよびpNPCから成る群より選択される、請 求項1または2の方法。 4.前記免疫原性構成物が二元担体構成物である、請求項1または2の方法。 5.前記二価性試薬がエチレンジアミン、1,6−ヘキサンジアミン、アジピ ン酸ジヒドラジド、シスタミン、グリシンおよびリジンから成る群より選択され る、請求項1または2の方法。 6.請求項1または2に従って製造された二元担体免疫原性構成物。 7.前記第一成分がデキストラン、肺炎球菌多糖、インフルエンザ菌多糖、ウ イルス多糖および細菌多糖から本質的に成る群より選 択される、請求項1または2の方法。 8.前記第二成分がBSA、百日咳トキソイド、破傷風トキソイド、マラリア 由来ペプチドP28、抗体、トキソイドおよび毒素から成る群より選択される、請 求項1または2の方法。 9.PT−Pn14、PT−PRP20、TT−Pn14、Hδa/1−デキストランおよび P28−TT −Pn14から本質的に成る群より選択される、請求項1または2に従って製造され た免疫原性構成物。 10.免疫応答を誘導する方法であって、 a) i) シアン化試薬を使って少なくとも1つの第一の炭水化物含有成分を活 性化し、そして ii) 前記活性化された炭水化物を第二成分に共有結合により結合させる ことにより免疫原性構成物を製造し; b) 前記免疫原性構成物を患者に投与する ことを含んで成る方法。 11.免疫応答を誘導する方法であって、 a) i) シアン化試薬を使って少なくとも1つの第一の炭水化物含有成分を活 性化し、 ii) 前記第一成分を二価性スペーサー試薬に共有結合により結合させ、そ して iii) 第二成分を段階b)の二価性スペーサー試薬に共有結合により結合させ る ことにより免疫原性構成物を製造し;そして b) 前記免疫原性構成物を患者に投与する ことを含んで成る方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12449193A | 1993-09-22 | 1993-09-22 | |
US08/124,491 | 1993-09-22 | ||
PCT/US1994/010658 WO1995008348A1 (en) | 1993-09-22 | 1994-09-21 | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09502978A true JPH09502978A (ja) | 1997-03-25 |
JP3828145B2 JP3828145B2 (ja) | 2006-10-04 |
Family
ID=22415196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50989795A Expired - Lifetime JP3828145B2 (ja) | 1993-09-22 | 1994-09-21 | 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法 |
Country Status (13)
Country | Link |
---|---|
US (2) | US5651971A (ja) |
EP (1) | EP0720485B1 (ja) |
JP (1) | JP3828145B2 (ja) |
KR (1) | KR100376361B1 (ja) |
AT (1) | ATE254475T1 (ja) |
AU (1) | AU678613B2 (ja) |
CA (1) | CA2171942C (ja) |
DE (2) | DE122009000058I1 (ja) |
ES (1) | ES2210262T3 (ja) |
FR (1) | FR12C0059I2 (ja) |
NL (2) | NL300412I1 (ja) |
NZ (1) | NZ274376A (ja) |
WO (1) | WO1995008348A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012051922A (ja) * | 2003-03-07 | 2012-03-15 | Wyeth Holdings Corp | 院内感染に対する免疫化のための多糖ブドウ球菌表面付着因子キャリアタンパク質接合体 |
Families Citing this family (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1262896B (it) * | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
US5849301A (en) * | 1993-09-22 | 1998-12-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents |
DE122009000058I1 (de) * | 1993-09-22 | 2009-12-31 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
NZ304715A (en) * | 1995-03-22 | 1999-07-29 | Jackson H M Found Military Med | Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten |
JPH11508225A (ja) * | 1995-04-17 | 1999-07-21 | ヘンリー エム.ジャクソン ファンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン | 細菌のリポ蛋白質を用いた多糖類に対する免疫応答の誘導および増強 |
US20030157129A1 (en) * | 1995-06-23 | 2003-08-21 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein |
US6447777B1 (en) * | 1996-03-29 | 2002-09-10 | David S. Terman | Polymerized staphylococcal protein a for treatment of diseases |
US6309646B1 (en) | 1996-05-09 | 2001-10-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates |
DK0912195T3 (da) | 1996-06-25 | 2009-05-18 | Pepscan Systems Bv | Vaccine indeholdende antigener bundet til bærestoffer gennem labile bindinger |
US6248334B1 (en) * | 1997-01-08 | 2001-06-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
WO1998047530A2 (en) * | 1997-04-24 | 1998-10-29 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines |
US5929049A (en) * | 1997-08-08 | 1999-07-27 | Dade Behring Marburg Gmbh | Polysaccharide conjugates of biomolecules |
WO1999039739A1 (en) * | 1998-02-05 | 1999-08-12 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media |
WO1999047168A2 (en) * | 1998-03-16 | 1999-09-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Induction and enhancement of the immune response to type-2 t cell-independent antigens conjugated to lipid or lipid-containing moieties |
WO1999052548A2 (en) * | 1998-04-10 | 1999-10-21 | Andrew Lees | Conjugate vaccines for the prevention of dental caries |
GB9808932D0 (en) * | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
CA2331258C (en) | 1998-06-12 | 2011-09-20 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220 |
BR9815953A (pt) * | 1998-07-20 | 2001-03-06 | Us Health | Vacinas contra infecção provocada por escherichia coli o157 |
US6858211B1 (en) * | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
US6585973B1 (en) | 1998-10-29 | 2003-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method for preparing solid phase conjugated vaccine |
US6797275B1 (en) * | 1998-12-04 | 2004-09-28 | The United States Of America As Represented By The Department Of Health And Human Services | Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine |
TR200102739T2 (tr) | 1999-03-19 | 2001-12-21 | Smithkline Beecham Biologicals S.A. | Aşı |
GB9909077D0 (en) | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
KR20070091698A (ko) * | 2000-06-29 | 2007-09-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 다가 백신 조성물 |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
US7534442B2 (en) * | 2001-08-21 | 2009-05-19 | The Brigham And Women's Hospital, Inc. | Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid |
AU2003257003A1 (en) * | 2002-07-30 | 2004-02-16 | Baxter Healthcare S.A. | Chimeric multivalent polysaccharide conjugate vaccines |
DK1549338T3 (da) | 2002-10-11 | 2011-03-28 | Novartis Vaccines & Diagnostic | Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
EP2289546A3 (en) | 2003-01-30 | 2011-03-30 | Novartis Vaccines and Diagnostics S.r.l. | Injectable vaccines against multiple meningococcal serogroups |
EP1961426B1 (en) | 2003-10-02 | 2011-04-27 | Novartis Vaccines and Diagnostics S.r.l. | Combined meningitis vaccines |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
AU2005209303A1 (en) * | 2004-01-29 | 2005-08-11 | Biosynexus, Inc. | Use of amino-oxy functional groups in the preparation of vaccines conjugates |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
SI1740217T1 (sl) | 2004-04-30 | 2011-10-28 | Novartis Ag | Konjugirano meningokokno cepljenje |
US7456000B2 (en) * | 2004-08-26 | 2008-11-25 | Siemens Healthcare Diagnostics Inc. | Deactivation of linking moieties in antibody-enzyme conjugates |
EP2305295B1 (en) | 2004-09-22 | 2015-04-01 | GlaxoSmithKline Biologicals SA | Antibody composition for use in vaccination against staphylococcei |
GB0505518D0 (en) | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
ATE548051T1 (de) | 2005-04-08 | 2012-03-15 | Wyeth Llc | Multivalente pneumokokken- polysaccharidproteinkonjugatzusammensetzung |
SI2283857T1 (sl) | 2005-06-27 | 2019-11-29 | Glaxosmithkline Biologicals Sa | Sestava cepiva, ki obsega konjugirane nativne kapsularne polisaharide n. meningitidis |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
DK1973564T3 (da) | 2005-12-22 | 2017-01-16 | Glaxosmithkline Biologicals Sa | Vaccine omfattende streptococcus pneumoniae-kapselpolysaccharidkonjugat |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
EP1993604B1 (en) | 2006-03-17 | 2015-12-02 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Methods for preparing complex multivalent immunogenic conjugates |
PT2004225E (pt) | 2006-03-22 | 2012-05-30 | Novartis Ag | Regimes para imunização com conjugados meningocócicos |
NZ595178A (en) | 2006-03-30 | 2013-03-28 | Glaxosmithkline Biolog Sa | Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus |
AU2007293672B2 (en) | 2006-09-07 | 2013-06-27 | Glaxosmithkline Biologicals S.A. | Vaccine |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
GB0700136D0 (en) | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
CN101687028A (zh) | 2007-05-02 | 2010-03-31 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗 |
EA201391788A1 (ru) | 2007-06-26 | 2014-08-29 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
CN102356089B (zh) | 2008-02-21 | 2014-02-19 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽 |
CA2739581A1 (en) | 2008-10-06 | 2010-04-15 | University Of Chicago | Compositions and methods related to bacterial eap, emp, and/or adsa proteins |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
JP5789250B2 (ja) | 2009-04-03 | 2015-10-07 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | プロテインA(SpA)変種に関連する組成物および方法 |
WO2011127032A1 (en) | 2010-04-05 | 2011-10-13 | University Of Chicago | Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response |
WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
WO2010141312A2 (en) | 2009-06-01 | 2010-12-09 | Wake Forest University Health Sciences | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same |
JP2012530785A (ja) | 2009-06-22 | 2012-12-06 | ワイス・エルエルシー | 組成物および黄色ブドウ球菌(Staphylococcusaureus)血清型5および8莢膜多糖コンジュゲート免疫原性組成物を調製するための方法 |
PE20142188A1 (es) | 2009-06-22 | 2014-12-29 | Wyeth Llc | Composiciones inmunogenicas de antigenos de staphylococcus aureus |
US8647621B2 (en) | 2009-07-27 | 2014-02-11 | Fina Biosolutions, Llc | Method of producing protein-carbohydrate vaccines reduced in free carbohydrate |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
EP2470204B1 (en) | 2009-08-27 | 2015-12-16 | GlaxoSmithKline Biologicals SA | Hybrid polypeptides including meningococcal fhbp sequences |
WO2011036560A2 (en) | 2009-09-23 | 2011-03-31 | Novartis Ag | Glycoconjugate compositions and methods for treatment of hiv |
EP2483390A2 (en) | 2009-09-30 | 2012-08-08 | Novartis AG | Expression of meningococcal fhbp polypeptides |
GB0917647D0 (en) | 2009-10-08 | 2009-11-25 | Glaxosmithkline Biolog Sa | Expression system |
AU2010310985B2 (en) | 2009-10-27 | 2014-11-06 | Glaxosmithkline Biologicals S.A. | Modified meningococcal fHBP polypeptides |
KR101605171B1 (ko) | 2009-12-17 | 2016-03-21 | 피나 바이오솔루션스, 엘엘씨 | 접합 백신 제조시 다당류를 활성화시키기 위한 화학 시약 |
GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
AU2010351576B2 (en) | 2010-04-23 | 2014-08-14 | FinaBioSolutions, LLC | Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels |
EP2588120B1 (en) | 2010-07-02 | 2017-11-15 | The University of Chicago | Compositions and methods related to protein a (spa) variants |
JP5793194B2 (ja) | 2010-09-09 | 2015-10-14 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 感染防御ブドウ球菌抗原が関与する方法および組成物 |
GB201106225D0 (en) | 2011-04-13 | 2011-05-25 | Glaxosmithkline Biolog Sa | Fermentation process |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
MX354924B (es) | 2011-11-07 | 2018-03-22 | Novartis Ag | Molecula portadora que comprende un antigeno spr0096 y un spr2021. |
GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
EP3805395A1 (en) | 2012-04-26 | 2021-04-14 | University Of Chicago | Staphylococcal coagulase antigens and methods of their use |
EP2906239A1 (en) | 2012-10-12 | 2015-08-19 | GlaxoSmithKline Biologicals SA | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
US10287330B2 (en) | 2012-12-27 | 2019-05-14 | Glaxosmithkline Biologicals S.A. | Methods and compositions relating to CRM197 |
WO2014135651A1 (en) | 2013-03-08 | 2014-09-12 | Crucell Holland B.V. | Acellular pertussis vaccine |
GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
BR112016004463A2 (pt) | 2013-09-08 | 2017-10-17 | Pfizer | composições de neisseria meningitidis e métodos das mesmas |
MY194920A (en) * | 2013-10-11 | 2022-12-23 | Msd Wellcome Trust Hilleman Laboratories Pvt Ltd | Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof |
WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
RU2688831C2 (ru) | 2014-01-21 | 2019-05-22 | Пфайзер Инк. | Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты |
NZ759686A (en) | 2014-01-21 | 2023-07-28 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
EP3099800B1 (en) | 2014-01-31 | 2020-10-14 | Fina Biosolutions LLC | Expression and purification of crm197 and related proteins |
BR112016019735A2 (pt) | 2014-02-28 | 2017-10-17 | Glaxosmithkline Biologicals Sa | fhbp, polipeptídeo, plasmídeo ou outro ácido nucleico, célula hospedeira, vesículas de membrana, e, composição imunogênica |
EP2921856B1 (en) | 2014-03-18 | 2016-09-14 | Serum Institute Of India Private Limited | A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines |
US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
AU2015359503B2 (en) | 2014-12-10 | 2019-05-09 | Glaxosmithkline Biologicals Sa | Method of treatment |
EP3034516A1 (en) | 2014-12-19 | 2016-06-22 | Novartis AG | Purification of streptococcal capsular polysaccharide |
ES2945312T3 (es) | 2015-01-15 | 2023-06-30 | Pfizer | Composiciones inmunogénicas para su uso en vacunas antineumocócicas |
WO2016154010A1 (en) | 2015-03-20 | 2016-09-29 | Makidon Paul | Immunogenic compositions for use in vaccination against bordetella |
SG11201708242YA (en) | 2015-05-04 | 2017-11-29 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
BR112017028130A2 (pt) | 2015-06-23 | 2018-08-28 | Biological E Ltd | vacina conjugada pneumocócica multivalente |
SG10202005253TA (en) | 2015-07-21 | 2020-07-29 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
EP3377098A1 (en) | 2015-11-20 | 2018-09-26 | Pfizer Inc | Immunogenic compositions for use in pneumococcal vaccines |
GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
US11191822B2 (en) | 2016-06-22 | 2021-12-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
EP3269385A1 (en) | 2016-07-12 | 2018-01-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
KR102467074B1 (ko) | 2016-08-05 | 2022-11-11 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
IL264552B2 (en) | 2016-08-05 | 2023-04-01 | Sanofi Pasteur Inc | A multivalent pneumococcal protein-polysaccharide conjugate preparation |
WO2018042017A2 (en) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
JOP20190038B1 (ar) * | 2016-09-06 | 2023-09-17 | Lg Chemical Ltd | تركيب اقتراني من السكر المتعدد لكبسولة بكتيريا المكورات الرئوية وبروتين حامل واستخداماته |
CN109789198A (zh) | 2016-09-30 | 2019-05-21 | 生物E有限公司 | 包含多糖-蛋白缀合物的多价肺炎球菌疫苗组合物 |
US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
EP3551668A1 (en) | 2016-12-06 | 2019-10-16 | GlaxoSmithKline Biologicals S.A. | Purification process for capsular polysaccharide |
WO2018134693A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
EP3576759A4 (en) | 2017-01-31 | 2020-11-11 | Merck Sharp & Dohme Corp. | PROCESS FOR THE PREPARATION OF CAPSULE POLYSACCHARIDE PROTEIN CONJUGATES FROM STREPTOCOCCUS PNEUMONIAE SEROTYPE 19F |
IL303108B1 (en) | 2017-01-31 | 2024-03-01 | Pfizer | NEISSERIA MENINGITIDIS preparations and methods therefor |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
MX2020002555A (es) | 2017-09-07 | 2020-09-25 | Merck Sharp & Dohme | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. |
US20210177957A1 (en) | 2017-12-06 | 2021-06-17 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
JP7446279B2 (ja) | 2018-07-19 | 2024-03-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 乾燥多糖を調製するための方法 |
EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
JP2022512345A (ja) | 2018-12-12 | 2022-02-03 | ファイザー・インク | 免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用 |
US20220054632A1 (en) | 2018-12-12 | 2022-02-24 | Glaxosmithkline Biologicals Sa | Modified carrier proteins for o-linked glycosylation |
AU2019401535B2 (en) | 2018-12-19 | 2023-12-14 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
CA3129425A1 (en) | 2019-02-11 | 2020-08-20 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
EP3952906A1 (en) | 2019-04-10 | 2022-02-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
CA3139257A1 (en) | 2019-05-10 | 2020-11-19 | Glaxosmithkline Biologicals Sa | Conjugate production |
EP3757217A1 (en) | 2019-06-27 | 2020-12-30 | GlaxoSmithKline Biologicals S.A. | Methods for protein purification |
EP4003410A1 (en) | 2019-07-31 | 2022-06-01 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
MX2022003682A (es) | 2019-09-27 | 2022-04-25 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
EP3799884A1 (en) | 2019-10-01 | 2021-04-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
US20220387614A1 (en) | 2019-11-22 | 2022-12-08 | Glaxosmithkline Biologicals Sa | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
AU2021224078B2 (en) | 2020-02-21 | 2024-01-18 | Pfizer Inc. | Purification of saccharides |
WO2021176409A1 (en) | 2020-03-05 | 2021-09-10 | Sanofi Healthcare India Private Limited | Preservative combination for vaccine composition |
EP3900739A1 (en) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein |
EP3919076A1 (en) | 2020-06-02 | 2021-12-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations |
CN115803050A (zh) | 2020-06-12 | 2023-03-14 | 葛兰素史克生物有限公司 | 使用纳米颗粒疫苗的细菌免疫 |
CN116209753A (zh) | 2020-06-25 | 2023-06-02 | 葛兰素史克生物有限公司 | 肺炎克雷伯氏菌o-抗原疫苗 |
GB202013262D0 (en) | 2020-08-25 | 2020-10-07 | Glaxosmithkline Biologicals Sa | Vaccine Composition |
EP4203995A1 (en) | 2020-08-26 | 2023-07-05 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
UY39428A (es) | 2020-09-17 | 2022-03-31 | Janssen Pharmaceuticals Inc | Composiciones de vacunas multivalentes y usos de las mismas |
CA3196222A1 (en) | 2020-10-20 | 2022-04-28 | Xianchao ZHU | Proteoglycan conjugate and application thereof |
JP2023546446A (ja) | 2020-10-22 | 2023-11-02 | ファイザー・インク | 細菌多糖を精製する方法 |
CN116744965A (zh) | 2020-11-04 | 2023-09-12 | 辉瑞大药厂 | 用于肺炎球菌疫苗的免疫原性组合物 |
WO2023111826A1 (en) | 2021-12-14 | 2023-06-22 | Glaxosmithkline Biologicals Sa | Bacterial immunization using qbeta hairpin nanoparticle constructs |
WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
CN114965784B (zh) * | 2022-06-01 | 2023-10-27 | 艾美探索者生命科学研发有限公司 | 多糖活化度的测定方法 |
GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
GB202208089D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE343210B (ja) * | 1967-12-20 | 1972-03-06 | Pharmacia Ab | |
NZ214503A (en) * | 1984-12-20 | 1990-02-26 | Merck & Co Inc | Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates |
DE3540076A1 (de) * | 1985-11-12 | 1987-05-14 | Boehringer Mannheim Gmbh | Verfahren zur stabilisierung von creatinkinase |
DE3541186A1 (de) * | 1985-11-21 | 1987-05-27 | Boehringer Mannheim Gmbh | Wasserloesliche, stabilisierte peroxidasederivate, verfahren zu ihrer herstellung und verwendung zur bestimmung von wasserstoffperoxid |
US5177059A (en) * | 1989-11-15 | 1993-01-05 | Sandoz Ltd. | Polymyxin B conjugates |
ES2063326T3 (es) * | 1989-11-15 | 1995-01-01 | Sandoz Ltd | Conjugados de polimixina. |
EP1958646A1 (en) * | 1992-02-11 | 2008-08-20 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Dual carrier immunogenic construct |
DE122009000058I1 (de) * | 1993-09-22 | 2009-12-31 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
-
1994
- 1994-09-21 DE DE122009000058C patent/DE122009000058I1/de active Pending
- 1994-09-21 CA CA2171942A patent/CA2171942C/en not_active Expired - Lifetime
- 1994-09-21 KR KR1019960701503A patent/KR100376361B1/ko not_active IP Right Cessation
- 1994-09-21 DE DE69433341T patent/DE69433341T2/de not_active Expired - Lifetime
- 1994-09-21 AT AT94929273T patent/ATE254475T1/de not_active IP Right Cessation
- 1994-09-21 ES ES94929273T patent/ES2210262T3/es not_active Expired - Lifetime
- 1994-09-21 WO PCT/US1994/010658 patent/WO1995008348A1/en active IP Right Grant
- 1994-09-21 JP JP50989795A patent/JP3828145B2/ja not_active Expired - Lifetime
- 1994-09-21 EP EP94929273A patent/EP0720485B1/en not_active Expired - Lifetime
- 1994-09-21 NZ NZ274376A patent/NZ274376A/en not_active IP Right Cessation
- 1994-09-21 AU AU78391/94A patent/AU678613B2/en not_active Expired
-
1995
- 1995-03-22 US US08/408,717 patent/US5651971A/en not_active Expired - Lifetime
- 1995-06-01 US US08/456,694 patent/US5693326A/en not_active Expired - Lifetime
-
2009
- 2009-09-24 NL NL300412C patent/NL300412I1/nl unknown
- 2009-09-24 NL NL300411C patent/NL300411I1/nl unknown
-
2012
- 2012-10-18 FR FR12C0059C patent/FR12C0059I2/fr active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012051922A (ja) * | 2003-03-07 | 2012-03-15 | Wyeth Holdings Corp | 院内感染に対する免疫化のための多糖ブドウ球菌表面付着因子キャリアタンパク質接合体 |
US8377451B2 (en) | 2003-03-07 | 2013-02-19 | Wyeth Holdings Corporation | Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
US9296795B2 (en) | 2003-03-07 | 2016-03-29 | Wyeth Holdings, Llc. | Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
Also Published As
Publication number | Publication date |
---|---|
AU7839194A (en) | 1995-04-10 |
ATE254475T1 (de) | 2003-12-15 |
EP0720485A1 (en) | 1996-07-10 |
DE69433341T2 (de) | 2004-04-15 |
FR12C0059I2 (fr) | 2016-10-21 |
KR960704572A (ko) | 1996-10-09 |
CA2171942C (en) | 2010-12-14 |
EP0720485B1 (en) | 2003-11-19 |
ES2210262T3 (es) | 2004-07-01 |
US5651971A (en) | 1997-07-29 |
AU678613B2 (en) | 1997-06-05 |
FR12C0059I1 (ja) | 2012-12-14 |
DE69433341D1 (de) | 2003-12-24 |
WO1995008348A1 (en) | 1995-03-30 |
KR100376361B1 (ko) | 2003-07-18 |
DE122009000058I1 (de) | 2009-12-31 |
JP3828145B2 (ja) | 2006-10-04 |
NZ274376A (en) | 1997-11-24 |
NL300411I1 (nl) | 2009-12-01 |
NL300412I1 (nl) | 2009-12-01 |
US5693326A (en) | 1997-12-02 |
CA2171942A1 (en) | 1995-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3828145B2 (ja) | 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法 | |
ES2200059T3 (es) | Produccion de construcciones inmunogenicas usando carbohidratos solubles activados mediante reactivos cianilados organicos. | |
CA2556169C (en) | Use of amino-oxy functional groups in the preparation of vaccines | |
AU728026B2 (en) | Preparation of protein-polysaccharide conjugate vaccines using homobifunctional and heterobifunctional vinylsulfones | |
US6087328A (en) | Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines | |
US5849301A (en) | Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents | |
US7166708B2 (en) | Process for preparing conjugate vaccines and the conjugate vaccines | |
CA2758323C (en) | Use of amino-oxy functional groups in the preparation of vaccines | |
JP5594612B2 (ja) | 有機シアン化試薬により活性化された可溶性炭水化物を使用する免疫原性構築物の製造 | |
NZ335984A (en) | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040426 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040727 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050314 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050425 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050913 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051213 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060313 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060606 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060706 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090714 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100714 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110714 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120714 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120714 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130714 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |